Contrast-enhanced harmonic endoscopic ultrasound-guided ethanol injection for a small hepatocellular carcinoma

Locoregional ablation represents the mainstay approach for early hepatocellular carcinoma (HCC). Percutaneous treatments are performed under ultrasound guidance to select a safe window to reach the nodule with a dedicated device [1]. We present a 76-year-old female patient, with hepatitis C-related cirrhosis, whose history included a wedge resection for a segment-6 HCC and subsequent transarterial chemoembolization. In 2014, computed tomography showed a 14-mm nodule with typical hallmarks for HCC located in the deep subcapsular portion of hepatic segment 2. Further surgery was contraindicated and percutaneous ablation was not feasible because of left portal vein interposition along the theoretical needle path. After multidisciplinary discussion, endoscopic ultrasound (EUS)-guided ethanol injection was attempted. A GF-UCT180 echoendoscope (Olympus, Japan) was used in conjunction with a Prosound-Alpha-10 system (Aloka, Japan). In order to adequately identify the tumor extent, contrast-enhanced harmonic EUS (CH-EUS) was used after Sonovue injection (Bracco International, Netherlands) [2]. A 22-gauge needle (Expect SlimLine; Boston-Scientific, USA) was inserted in the deepest portion of the nodule and 10 mL of ethanol were injected (Fig. 2). The procedure was well tolerated and no adverse events occurred.

Contrast-enhanced ultrasound 40 days later showed suspected persistence of the HCC. CH-EUS showed a mainly non-enhanced area in the region that had been previously treated, which was compatible with necrosis. However, in its peripheral portion, a tiny (3-mm) residual arterial vascularization was confirmed (Fig. 3). In the same session, the patient underwent an uneventful second ethanol injection (3 mL) under CH-EUS guidance (Fig. 4, Video 1).

Follow-up at 3, 6 and 12 months with computed tomography showed neither local nor distant recurrence. The patient continued follow-up for a further 8 months until death from causes unrelated to her liver. This case suggests that EUS-guided ablation of HCC represents a valid alternative to percutaneous ablation when the latter is not feasible or is contraindicated. Interestingly, CH-EUS may help to identify viable areas of HCC and allow targeted treatment under direct dynamic visualization of tumor vessels [3–5].
Competing interests

None

The authors

Andrea Lisotti¹, Fabio Piscaglia², Pietro Fusaroli¹

¹ Gastroenterology Unit, Department of Medical and Surgical Sciences, University of Bologna/Hospital of Imola, Italy
² Internal Medicine Unit, Department of Medical and Surgical Sciences, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy

Corresponding author

Pietro Fusaroli, MD
Gastroenterology Unit, Hospital of Imola, Via Montericco 4, 40026 Imola (BO), Italy
Fax: +39-0542-662409
pietro.fusaroli@unibo.it

References


Bibliography

DOI https://doi.org/10.1055/a-0915-1385
Published online: 2019
Endoscopy
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X

Fig. 2 EUS-guided ethanol ablation of the 14-mm hepatic segment-2 HCC.

Fig. 3 Identification of a small (2–3-mm) residual HCC on CH-EUS. Time: 27 seconds after contrast injection.

Fig. 4 EUS evaluation after second ethanol injection into the residual HCC.